Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSeek, a subsidiary of Asterand, has reached the first research milestone in the multi-year drug discovery partnership with Ono Pharmaceutical.
Subscribe to our email newsletter
Under the collaboration, to a target drug candidate selected by Ono, BioSeek is utilizing its proprietary BioMAP platform to conduct phenotypic screening, hit identification, lead optimization and clinical candidate selection.
As per the agreement, Ono has gained rights to develop and market all pharmaceutical products discovered under the collaboration.
BioMAP Systems are primary cell-based models of human disease biology which are designed to replicate the intricate cell and pathway interactions.
Evalaution of candidates through BioMAP provides early insight into human pharmacological and toxicological properties of compounds, including on-and off-target effects, dose responses, and the discrimination of closely related compounds.
Asterand chairman and Interim CEO Jack Davis said they value their relationship with Ono since it enables them to take full advantage of BioMAP’s power to discover and develop new drug candidates.